# Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany

> **NCT01155193** · — · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 30804 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01155193
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09-01
- **Primary completion:** 2016-07-31
- **Final completion:** 2016-07-31
- **Target enrollment:** 30804 (ACTUAL)
- **Last updated:** 2018-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01155193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01155193, "Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01155193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*